Table 1.

Patient characteristics

	Dose group
	<70 Gy (n = 43)	70–74.9 Gy (n = 552)	75–79.9 Gy (n = 568)	≥80 Gy (n = 367)	All (n = 1,530)
Median age	73 y	69 y	68 y	69 y	69 y
Median follow-up	85.9 mo	67.8 mo	54.6 mo	45.6 mo	55.4 mo
Stage T1–T2	43 (100%)	522 (95%)	545 (96%)	351 (96%)	1,461 (96%)
Stage T3–T4	0 (0%)	30 (5%)	23 (4%)	16 (4%)	69 (4%)
GS 2–6	42 (98%)	441 (80%)	460 (81%)	165 (45%)	1,108 (72%)
GS 7	1 (2%)	98 (18%)	86 (15%)	188 (51%)	373 (24%)
GS 8–10	0 (0%)	13 (2%)	22 (4%)	14 (4%)	49 (4%)
iPSA <10	25 (58%)	362 (66%)	350 (62%)	213 (58%)	950 (62%)
iPSA 10–20	12 (28%)	127 (23%)	152 (27%)	125 (34%)	416 (27%)
iPSA >20	6 (14%)	63 (11%)	66 (11%)	29 (8%)	164 (11%)
Low-risk	24 (56%)	299 (54%)	296 (52%)	64 (17%)	683 (45%)
Intermediate-risk	13 (30%)	164 (30%)	174 (31%)	247 (67%)	598 (39%)
High-risk	6 (14%)	89 (16%)	98 (17%)	56 (16%)	249 (16%)

Abbreviations: PSA = prostatic-specific antigen; GS = Gleason score.